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Summary: A comparison o f labelling compounds w i t h chloramine-T and w i t h 1,3,4,6-tetrachloro-3a, 6a-diphenyl-
glycoluril ( Iodogen®) has been carried out. 
For human transferrin, human calcitonin, 1-84 bovine parathyrin, fibrinopeptide-A, human thyrotropin and F-CB3, a 
cyanogen bromide cleavage peptide o f human fibrinogen, the quality o f tracer produced by the Iodogen method was 
better. For rat lu t ropin, human growth hormone and human prolactin, labelling w i t h Iodogen produced a tracer o f 
unsatisfactory quality. For a further 13 peptides, the results from both methods were comparable. 
Optimal reaction times using Iodogen were o f the magnitude o f two to three times longer than when using chlor-
amine-T. Reduction o f the volume o f radioactive waste by up to 90% could be achieved when the Iodogen method 
was coupled w i t h a short cation-exchange column to separate unreacted iodide from the labelled compound. Data is 
presented on the quality o f tracer, expressed in terms o f elution profiles and radioimmunoassay standard curves. 
A novel "combi-method" o f labelling proteins wi thout tyrosine or histidine moieties is presented where N-succin-
imidyl-3-(4-hydroxyphenyl)-propionate is labelled at pH 7.5 using Iodogen to give "Bolton-Hunter" reagent, which 
is then transferred to a vessel containing the peptide to be labelled at pH 8.6. 
Erfährungen mit Chloramin-T und Iodogen® für die lodierung von Peptiden für Radioimmunoassays 
Zusammenfassung: Es wurde eine Vergleichsuntersuehung zweier Methoden zur Radioiodierung von Peptiden unter 
Verwendung von Chloramin-T und 1, 3 , 4 , 6-tetrachlor-3a, 6a-diphenylglycoluril (Iodogen) als Oxidans durchgeführt . 
Die Iodierungsergebnisse waren von Peptid zu Peptid unterschiedlich. Bessere Ergebnisse der Iodogenmarkierung wur-
den bei humanem Transferrin, humanem Calcitonin, 1-84 bovinem Parathormon, Fibrinopeptid-A, F-CB3 (einem 
Bromcyan-Spaltprodukt des humanen Fibrinogens) und humanem Thyrotropin beobachtet. Dagegen sind die Iodogen-
tracer von Ratten-Lutropin sowie humanem Prolactin und humanem Wachstumshormon nicht brauchbar gewesen. 
Vorteile der Verwendung von Iodogen waren die längeren Markierungszeiten sowie die Verminderung der radioakti-
ven Abfälle (um 90%), wenn die Trennung von gebundenem und freiem Iodid mi t Hilfe einer kurzen Ionenaustau-
schersäule erfolgte. 
Eine neue „Combi -Methode" für Peptide ohne Tyrosin bzw. Histidinreste wird beschrieben, wobei N-Succinimidyl-3-
(4-hydroxyphenyl)propionat zuerst bei pH 7,5 mi t Iodogen markiert wurde. Anschließend wurde dieses „Bolton-
Hunter" Reagens in einem zweiten Gefäß dem zu markierenden Peptid bei pH 8,6 hinzugefügt, wo die Iodie-
rungsreaktion dann stattfand. In diesem Bericht werden die erreichte Iodinkorporation sowie die Qual i tä t der herge-
stellten Tracer anhand von Standardkurven bzw. Elutionsprofilen mitgeteilt . 
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Introduction 
Iodination w i t h chloramine-T has been carried out 
routinely for many years (1) . The advantage o f this 
method over its predecessors (electrolytic iodination, 
oxidation w i t h iodine monochloride), was the higher 
yield and specific activity o f the products, coupled w i t h 
a rapid and simple procedure. A disadvantage is the 
possible alteration o f the physico-chemical properties 
o f the substance to be labelled under the strong oxida-
t ion conditions. 
In order to overcome these side-effects, lactoperoxidase 
was substituted for chloramine-T (2—5), and although 
here, the reaction sequence is more complicated than 
w i t h chloramine-T, the quality o f the products in terms 
o f immuno- and bio-activity is often better. 
The introduction o f Iodogen as oxidant (6 , 7) has led to 
a new procedure which is both simple and effective, and 
which usually gives rise to iodinated tracers o f high 
quali ty. When this method is used in conjunction w i t h a 
short cation-exchange column for desalting the iodina-
t ion mixture , up to 90% o f the radioactive waste 
produced by chloramine-T and a conventional gel-filtra-
t ion desalting step falls away. 
As Iodogen is water insoluble, but is very soluble in 
chloroform, i t can be used to plate vessel walls by pipett-
ing a solution o f Iodogen in chloroform to reaction 
vessels and then allowing the chloroform to evaporate 
o f f in a fume cupboard. I f the resulting tubes are then 
stoppered and stored in a closed vessel containing silica 
gel at - 20 °C, they are stable for several months. A l -
though the reaction mechanism o f both chloramine-T 
and Iodogen is the same, the fact that the Iodogen is 
immobilised means that i t comes into less contact w i t h 
the compound to be labelled, which in turn leads to less 
unwanted side-effects. 
Materials and Methods 
Chloramine-T, sodium metabisulphite and buffer chemicals were 
purchased from Merck, Darmstadt, FRG. Iodogen and N-succin-
imidyl-3-(4-hydroxyphenyl) propionate were obtained from 
Pierce Eurochemie BV. Rotterdam, NL. Sephadex gels were 
purchased from Pharmacia, Freiburg i.Br. FRG, Ultrogel from 
LKB, Munich and Biogel from Bio-Rad, Munich, FRG. Sodium 
1 2 5 iodide was obtained from Amersham-Buchler, Brunswick, 
FRG. 
The proteins and hormones were obtained from the following 
sources: Human transferrin, human caeruloplasmin and human 
Gc-protein were purchased from Behringwerke, Marburg a.d. 
Lahn, FRG. 
1-32 human calcitonin (hCT) and 1-34 human parathyrin 
(1-34 hPTH) were donated by Prof. R. Ziegler, Heidelberg, FRG. 
1-84 bovine parathyrin (1-84 bPTH) was purchased from Inolex 
(Lot Nos. 1515-A001 and 1515 C001) Chicago, Illinois USA. 
44-68 human parathyrin (44-68 hPTH) was a generous gift 
from Prof. R. D. Hesch, Hannover, FRG. 
Human prolactin (hPRL) and human growth hormone (hGH) 
were given by Prof. K. von Werder, Munich, FRG. 
Fibrinopeptide-A, (FPA), Factor V I I I clotting activity (FVIIIC), 
antibodies to Factor V I I I related antigen (Anti FVIIIR) and anti-
bodies to FVIIIC (Anti FVIIIC) were from Dr. W. Schramm 
Munich, FRG. 
High molecular weight kininogen (HMWK) was from Prof. 
H. Fritz, Munich, FRG. 
F-CB3, a cyanogen bromide cleavage product of human fibrino-
gen was generously donated by Dr. Rotraut Gollwitzer, Martins-
ried, FRG. Human choriongonadotropin was provided by 
Dr. K. Mann, Munich, FRG. Human endorphins and 1-24 cor-
ticotropin (ACTH 1-24) were bought from Serva Heidelberg, 
FRG. 
Human thyrotropin (hTSH) was purchased from Kabi AB Stock-
holm, S. Rat lutropin (rLH) was supplied by Dr. G. Emons, Lü-
beck, and cortisol-3-tyrosyl methyl ester was synthesised by 
Dr. G. Stalla, Munich, FRG. 
Labelling wi th chloramine-T and Iodogen 
Chloramine-T 
Dissolve 10 mg chloramine-T and 10 mg sodium metabisulphite 
each in 10 ml 0.05 mol/1 phosphate buffer, pH 7.5 (for labelling 
tyrosine moieties) or pH 8.4 (for histidine moieties). Add the 
components to the reaction vessel in the following order: peptide 
to be labelled (10 ß\), N a 1 2 5 I in 0.5 mol/1 phosphate buffer, 
pH 7.5 or 8.4 (20 ß\ = 37.2 MBq) and chloramine-T (10 jul) and 
mix. After reaction (5-30 seconds) add sodium metabisulphite 
(50 p\), rnix and transfer the reaction mixture to a Sephadex 
G-10 column ( 9 X 1 cm) and elute with 0.05 mol/1 Tris-HCl 
buffer, pH 7.5 containing bovine serum albumin (10 mg • liter"1). 
Count the fractions and collect the first peak. This is then either 
diluted for use, or rechromatographed on a second column of 
suitable material (e.g. Sephadex, Ultrogel or Biogel) if necessary. 
Iodogen 
I . Coating the vessels 
Pipette 25 jttl of Iodogen in chloroform (0.2 g • liter"1) into poly-
propylene iodination vessels (Eppendorf 3811 or Sarstedt 696) 
and allow the chloroform to evaporate off in a fume cupboard. 
The vessels are then stoppered and stored in a sealed vessel con-
taining a dessicant (silica gel) at - 20 °C until required (shelf life 
in excess of six months). 
2. Labelling 
The substance to be labelled (20 p\) is pipetted into the vessel 
containing the Iodogen followed by 37 MBq N a 1 2 5 I in 0.5 mol/1 
phosphate buffer pH 7.5 or 8.4 (20 MD- The vessel is shaken 
during the reaction time (15-60 seconds) and the contents then 
transferred to a Sephadex SP-C25 desalting column ( 2 X 1 cm) 
equilibrated to pH 3.0 with 0.01 mol/1 glycine-HCl buffer. The 
same buffer is then used to elute off unreacted iodide, the pep-
tide peak being eluted off using 0.5 mol/1 phosphate buffer 
pH 7.5. The second peak is either diluted with assay buffer for 
use, or rechromatographed if necessary as described above for 
chloramine-T. The time taken up to the completion of the 
desalting step is 25-40 min for Iodogen and 60-75 min for 
chloramine-T. 
Results 
Effects of Iodogen concentration 
and time of radioiodination 
Figure 1 shows the effects o f Iodogen concentration 
and labelling time on the elution profile o f 1 -84 bovine 
parathyrin, together w i t h the maximum binding in the 
fractions showing immunoreactivity. As a comparison, 
the labelling w i t h chloramine-T ran identically w i t h the 
Iodogen 25/90 labelling on the same column. 
J. Clin. Chem. Clin. Biochem. / Vol. 19, 1981 / No. 10 
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Fig. 1 . The effect of the amount of Iodogen used, and of the 
labelling time upon the elution profile and binding charac-
teristics of bovine parathyrin (1-84 bPTH). The column 
used was Ultrogel AcA-44 (130 X 2.5 cm) using 0.1 mol/1 
ammonium acetate buffer, pH 4.5 . 
o o 25 Mg Iodogen/90 s labelling-Max. binding in frac-
tions 3 9 - 4 2 . B 0 / T = 0 .31 
A — A 25 Mg Iodogen/200 s labelling-Max. binding in 
fractions 3 8 - 4 1 . B 0 / T = 0.28 
• • 5 Mg Iodogen/60 s labelling-Max. binding in frac-
tions 3 6 - 3 9 . BQ/T = 0 .32 
A A 5 jug Iodogen/30 s labelling-Max. binding in frac-
tions 3 6 - 3 9 . B 0 / T = 0 .34 
The void volume of the column is 1 1 8 ml which corre-
sponds to the first 25 fractions (4.75 ml each) collected. 
Increasing the concentration o f Iodogen and the reac-
t ion time leads to a progressive alteration o f the elution 
profile to the detrement o f the immunological activity 
o f the tracer. The same effect is seen w i t h increasing the 
reaction time using chloramine-T. The conditions for 
the chloramine-T labelling giving the same result as the 
Iodogen labelling using 25 ßg for 90 seconds are shown 
in table 1, which also shows the optimal times o f 
labelling, in terms o f maximal incorporation w i t h 
minimal damage, for several peptides under the condi-
tions laid down in "Materials and Methods". 
Quality of label produced together with iodine incorpo-
ration 
Table 2 shows the maximum binding obtained w i t h 
Iodogen-labelled tracers for five proteins or peptides. 
Figures 2 and 3 show elution profiles o f tracer produced 
by chloramine-T for human transferrin, compared w i t h 
tracer produced by the Iodogen method. Both iodina-
tions were carried out wi th in 30 minutes o f each other 
using the same sodium 1 2 5 i o d i d e . 
The differing 50% intercepts shown in table 2 reflect 
the differing affinity o f the peptides for the antibody 
after labelling. 
Tab. 1. Optimal conditions for labelling with chloramine-T and 
Iodogen under the conditions stated in the text. 
Ligand Amount Chlor- Iodogen 
amine-T 
(jug) Labelling time 
(seconds) 
Human transferrin 10 5- 10 30--45 
1-84 Bovine parathyrin 5 10- 15 30--45 
*44-6 8 Human parathyrin 2 5- 10 30--45 
Human calcitonin 5 5-•10 20--30 
*Fibrinopeptide-A 5 15- 20 30--45 
Human fibrinogen fragment 
F-CB3 10 10- 15 30--45 
Human choriongonado-
tropin 5 10- 15 30--45 
Human choriongonado-
tropin a-subunit 5 10- 15 20--30 
Human thyrotropin 5 10- 15 20--30 
Factor VI I I clotting 
activity (FVIIIC) 5 ** 20--30 
Antibodies to FVIIIC 10 15-•20 30 -45 
Antibodies to factor VI I I 
related antigen 10 15- 20 30--45 
High molecular weight 
kininogen 5 2- 5 10 -15 
a-Endorphin 2 10- 15 20--30 
0-Endorphin 2 10- 15 20--30 
Corticotropin 1-24 2 5- 10 15--20 
Caeruloplasmin 10 5- 10 15--20 
Gc Protein 5 10- 15 20--30 
Cortisol-3-tyrosyl-
methylester 1 20- 30 45--60 
* Both of these peptides contained a tyrosine residue at the 
NH2-terminus. 
** Factor VIII clotting activity was not labelled with chlor-
amine-T 
Figure 4 shows a standard curve for parathyrin using 
tracer from both iodination methods. 
Stability of tracers 
Tracers from both methods kept under identical condi-
tions, i.e. diluted in assay buffer to ca. 7—10 MBq/1 
and stored at - 20 °C were equally stable in most cases, 
when optimal labelling methods were used. 
Anomalous results 
Figure 5 shows the labelling o f factor V I I I clotting activ-
i ty w i t h Iodogen. The protein peak appeared to be 
missing when the normal elution procedure was carried 
out, together w i t h a large proportion o f the radioactivity. 
When, however, Tween 20 (0.25%) was incorporated 
into the phosphate buffer, the protein was eluted, thus 
demonstrating its lipophilic nature. 
Several peptides were not successfully labelled w i t h 
Iodogen, despite several attempts. Whether this was a 
property o f the peptides as a whole, or just o f the mate-
J. Clin. Chem. Clin. Biochem. / Vol. 19,1981 / No. 10 
1054 Wood, Wächter and Scriba: Radioiodination using chloramine-T and Iodogen 
Tab. 2. Effects of labelling with chloramine-T and Iodogen on the maximum binding (Max-B) , binding of the zero standard under 
assay conditions (B 0 ) , the unspecific binding under assay conditions (UB) and the 50% intercept of the standard curves run 
at the same time using the two tracers. 
Assay Chloramine-T Iodogen 
B 0 UB Max-B 50% intercept Bo UB Max-B 50% intercept 
Human transferrin 0.60 0.04 0.84 2.05 g • r 1 0.85 0.03 0.99 2.01 g • r 1 
Human calcitonin 0.22 0.02 0.80 820 ng • 1 _ 1 0.31 0.03 0.95 795 ng • f 1 
1-84 Bovine parathyrin 0.12 0.03 0.61 3.12Mg-l - 1 0.20 0.03 0.71 2.05 /ug • r 1 
1-84 Human parathyrin 0.24 0.03 0.78 517 u-r 1 0.38 0.03 0.85 526 u • r 1 
44-68 Human parathyrin 0.27 0.03 0.75 485 u • r 1 0.38 0.03 0.82 447 u . r 1 
B 0 was the binding of the zero standard under assay conditions with respect to the total activity (Bo/T) 
UB was the unspecific binding under assay conditions (UB/T) 
Max-B was the binding of fresh tracer to an excess of antibody (B/T) 
The 50% intercept of the standard curve run under assay conditions reflects the affinity of the antibody for the two tracers. 
Full assay details are to be seen in I.e. (10-12). 
[ 1 2 5 I ] Transferrin 
0.5mol/l Phosphate buffer pH7.5 
130000 • 
110 000 
90000 -
" 70 000 -
50 000 -
30 000 
10 000 h 
10 12 14 16 1B 20 22 24 
Fraction No. 
Fig. 2. Elution profile of the labelling mixture from the chlor-
amine-T iodination of human transferrin. The first peak 
contains the 1 2 5I-transferrin which bound to excess anti-
body with a B/T of 0.85. The column was Sephadex G-10 
(9 X 1 cm) with 0.05 mol/1 Tris-HCl pH 7.5 containing 
bovine serum albumin (1 g • l i ter - 1 ) as elution buffer. The 
void volume of this column was 4 ml, corresponding to 
the first four fractions collected. 
150000 
130000 
^110000 -
90 000 
70 000 
50 000 
30 000 
10 000 
10 12 
Fraction No. 
rial which was tested, has not been investigated due to 
reasons o f cost! Trouble was encountered w i t h human 
prolactin, human somatotropin and rat lu t ropin , the 
former two producing a tracer w i t h high incorporation 
but high unspecific binding whereas the latter produced 
an incorporation o f ca. 2% despite lengthening the 
reaction time to 15 minutes! Other workers have also 
had problems (8) . Where the hormones are not men-
tioned, labelling w i t h chloramine-T and Iodogen gave 
rise to tracers o f comparable quality and stability as 
well as similar iodine incorporation. 
Fig. 3. Elution of human transferrin labelled with Iodogen, 
separated on a Sephadex SP-C25 cation exchange column 
(2 X 1 cm) using 0.01 mol/1 glycine-HCl buffer, pH 3.0 
to elute off the iodide and 0.5 mol/i phosphate buffer to 
elute off the labelled transferrin. The label bound to 
excess antibody with a B/T of 0.99. Note that in contrast 
to figure 2, the iodide peak is eluted from the column 
first. 
"Combi-labelling" with Iodogen 
The immobilised Iodogen was used to facilitate the 
labelling o f proteins and peptides w i t h "Bolton-Hunt er" 
reagent (N-succinimidyl-3-(4-hydroxyphenyl) propionate). 
J. Clin. Chem. Clin. Biochem. / Vol. 19,1981 / No. 10 
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1.00O-
0.60 
0.40 
0.20 
0.01 0.10 1.00 
Bovine parathyrin [jig/i] 
10.0 
Fig. 4. Bovine parathyrin RIA standard curves run under identi-
cal conditions. 
• • Chloramine-T label, binding of zero standard in 
the assay. B 0 / T = 0.12 
• — A Iodogen label, binding of zero standard in the 
assay. B 0 /T = 0.19 
(For full assay details see 1. c. (10)) 
Figures 6 and 7 show the labelling o f 1-34 human para-
thyr in w i t h chloramine-T at p H 8.4 (labelling o f histidine 
residues), and using the "combi-labelling" method. A n 
excess "Bolton-Hunter" reagent must be added to com-
pensate for loss due to hydrolysis during iodination. 
Discussion 
Although the mechanism o f action o f Iodogen and chlor-
amine-T is similar, namely by the action o f chlorinium 
ions which oxidise iodide to atomic iodine and to iodi-
n ium ions, the immobilisation o f Iodogen on the vessel 
wall reduces the potential hasard o f structural changes 
during iodination (fig. 8). The longer incubation time o f 
the reagent w i t h Iodogen reduces the hectic which can 
occur during labelling w i t h chloramine-T. In several 
cases, the quality o f tracer produced by Iodogen is better 
than that from chloramine-T, although there are cases 
where the Iodogen method produced a tracer which 
could not be used in a radioimmunoassay, but where 
tracer produced by reacting the material w i th chlor-
amine-T and iodide was excellent in the same assay. 
0.01 mol/l Glycine/HCl pH 10 
"Iodide 10L5mol/l Phosphote buffer pH 7.5 
50000 
60000 -
40 000 
20 000 -
10 000 
6 8 10 
Froction No. 
Fig. 5. Elution of factor V I I I clotting activity (FVIIIC) after 
Iodogen labelling. The total activity was 204600 counts/ 
10 s, the remaining activity on the vessel after labelling 
20000 counts/10 s. From the elution profile both the 
labelled protein peak and ca. 100000 counts/10 s are 
missing. This activity can be washed from the column 
with 0.5 mol/l phosphate buffer, pH 8 containing 2.5 g/1 
Tween 20, and demonstrates the lipophilic nature of 
factor VI I I clotting activity. 
Here time and money could be saved by first labelling 
the "Bolton-Hunter" reagent w i t h Iodogen at p H 7.4 
w i t h subsequent transfer o f tube contents to a second 
vessel containing the peptide to be labelled at pH 8.6— 
9.0 (9) . As the Iodogen is bound to the tube wal l , i t is 
not transferred w i t h the "Bolton-Hunter" reagent, thus 
preventing transfer o f unwanted oxidation agents to the 
second vessel. 
40000 
I 30000 
120000 
10000 
30 40 50 
Froction No. 
Fig. 6. Elution of human parathyrin 1-34 peptide on Ultrogel 
AcA 54 after labelling with chloramine-T at pH 8.4. The 
large peak contains the immunoreactive peptide 
(B 0 /T = 0.59, UB/T = 0.06) and the two preceding peaks 
aggregated material with high unspecific binding (UB). 
The column dimensions were the same as described in 
figure 1 as was the elution buffer. 
J. Clin. Chem. Clin. Biochem. / Vol. 19,1981 / No. 10 
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11000 
£ 5 500 
Human parathyrin Human calcitonin 
1-84 i . 1-32 | r 
10 20 30 
Fraction No. 
40 50 
Fig. 7. Elution of human parathyrin 1-34 peptide on Ultrogel 
AcA 44 after "combi-labelling" with Iodogen and Bolton-
Hunter reagent. The large peak contained all the immuno-
reactive peptide, which showed a relatively high unspecific 
binding (B 0 /T = 0.62, UB/T = 0.13). Marker proteins, 
1-84 bovine parathyrin (1-84 bPTH),and 1-32 human 
calcitonin (1-32 hCT) indicate that the labelled 1-34 
human parathyrin elutes at the expected point. The void 
volume of the column was 158 ml, and the dimensions 
and elution buffer the same as in figure 1. 
For proteins and peptides which are resistant to oxida-
t ion , Iodogen labelling may offer a more comfortable 
method o f iodination, coupled w i t h a drastic reduction 
in the volume o f radioactive waste when the reaction is 
coupled w i t h the desalting step using the short cation-
exchange column here described. 
There are cases where, due to a lack o f tyrosine or 
histidine residues, or where a non-oxidative iodination is 
desired to prevent groups such as the -SH o f cysteine and 
cr + cr-*ci 2 
Cl 2 + H 2 0 - H C 1 + HOG 
HOC1 
CH 3 
S -
I 
R 
neutral 
non-polar 
CH 3 
S=0 
I 
R 
HOC1 
CH 3 
0=S=0 
I 
R 
acidic 
polar 
Methionine + 2HOC1 Methionine sulphone -f 2HC1 
SH 
I 
CH 2 
I 
R 
HOC1 
S=0 
I 
-CH 2 
HOC1 
neutral 
reducing 
OH 
I 
o=s=o 
I 
- CH 2 
R 
acidic 
non-reducing 
1 Cysteine + 3HOC1 -> Cysteine sulphonic acid + 3 HCl 
and 
2 Cysteine + HOC1 -* Cystine + HCl + H 2 0 
Fig. 8. Possible unwanted side effects which may lead to struc-
tural changes in peptides during labelling with chlor-
amine-T and Iodogen. 
the -S-CH 3 groups o f methionine being destroyed. Here 
the free N H 2 -groups ( e -NH 2 o f lysine) must be iodinated, 
and the "combi-method" may prove to be useful in 
such cases. 
To conclude, an alternative to chloramine-T and lacto-
peroxidase is presented by the introduction o f Iodogen, 
although, like many innovations, it has its advantages 
and disadvantages which can only be tested by trial and 
error. 
The fu l l details o f the assay conditions for parathyrin 
(10), human calcitonin (11) and human transferrin (12) 
have been published in ful l elsewhere. 
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